Pα+ Psychedelic Bulletin #216: Australia veteran PAP funding, New Mexico medical psilocybin timeline, Radial $50M, Otsuka CNS compounds, more

Pα+ Psychedelic Bulletin #216 compiles multiple policy and development updates across psychedelics, with Australia’s veteran psychedelic-assisted psychotherapy funding taking center stage. Australia’s Department of Veterans’ Affairs explains a world-first reimbursement model for psychedelic-assisted psychotherapy (PAP). The bulletin notes the program covers psilocybin for treatment-resistant depression (TRD) and PTSD for eligible veterans, including process details such as sign-off authority and the framing of responsible administration. The bulletin also reports that New Mexico targets December 2026 for a medical psilocybin launch. It highlights Radial raising $50M to advance interventional psychiatry and discusses Otsuka signaling work on “psychedelic-inspired” CNS compounds. Additional items include a preprint suggesting psilocybin promotes growth of existing brain tumours in mice, a $50M award to a Texas ibogaine study consortium, and Czech efforts to draft guidelines for psilocybin therapy with a 2026 launch target.